Breast cancer treatment
171 – 180 of 216
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma
(
- Contribution to journal › Article
-
Mark
Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection : The randomized controlled SENOMAC trial
(
- Contribution to journal › Article
-
Mark
Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder : Association with tumor stage, lymph node metastases, FDG-PET findings, and survival
(
- Contribution to journal › Article
-
Mark
Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy
(
- Contribution to journal › Article
-
Mark
Androgen receptor expression and breast cancer mortality in a population-based prospective cohort
(
- Contribution to journal › Article
-
Mark
AIB1 is a new putative prognostic biomarker in the luminal A and B-like (HER2-negative) classification of invasive lobular carcinoma
(
- Contribution to conference › Abstract
-
Mark
Quality of up to 35 years old archival breast cancer tissue in paraffin-blocks for estrogen receptor evaluation
(
- Contribution to journal › Published meeting abstract
- 2016
-
Mark
St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.
(
- Contribution to journal › Article
-
Mark
A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation
(
- Contribution to journal › Article
-
Mark
Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer : Long-Term follow-up (> 25 years) of the phase III SBII:2pre trial
(
- Contribution to journal › Article